What the April 2026 Announcement Changes The FDA's April 15 announcement signals that injectable GHK-Cu will be removed from the Category 2 list, with formal implementation expected in July 2026 when the FDA's peptide advisory panel is scheduled to reconvene and finalize updated guidance
Product Details Available sizes: 500mg, 600 mg, 1200 mg, and 1500 mg Form: Lyophilized powder Testing: Independent third-party testing COA: Available by lot Origin: Manufactured in the USA Packaging: Sealed vial Storage: Refrigerate between 2C and 8C
WARNHINWEISE: Das Nahrungsergnzungsmittel ersetzt nicht eine abwechslungsreiche, ausgewogene Ernhrung und eine gesunde Lebensweise
IGF-1LR3 IGF-1 LR3 is a synthetic analog of IGF-1, engineered with: Arginine substitution at position 3 (Arg3) Extended peptide sequence Benefits include: \Muscle Growth: Increases lean body mass via satellite cell proliferation and differentiation
[14] Epitalon appears to inhibit the synthesis of the MMP9 protein in vitro in aging skin fibroblasts
Archived from the original (PDF) on 27 July 2008